Swiss pharmaceutical giant Roche says it has signed an agreement to purchase 100 per cent of Californian company, BioImagene.
This content was published on
1 minute
The deal, worth $100 million (SFr105 million), is being carried out by a Roche subsidiary in the United States, Ventana Medical Systems Inc.
Roche said in a statement that BioImagene, “is an innovative leader in the field of digital pathology workflow and analysis”.
This technology enables the capturing of images, analysis of these images and the online sharing of patients’ tissue samples.
“As part of the personalised healthcare approach, pathologists are increasingly involved in generating information with high impact on treatment decisions,” said Daniel O’Day, COO Roche Diagnostics.
“The increasing complexity of new tests and technologies creates tremendous need for more sophisticated tools for tissue analysis and diagnosis,” O’Day added.
The transaction is subject to customary closing conditions and is expected to close in the coming weeks.
In the first half of this year, Roche reported that net profit climbed by 37 per cent to SFr5.6 billion ($5.3 billion).
swissinfo.ch and agencies
Popular Stories
More
Swiss Abroad
How centuries of Swiss emigrants left their mark on the US
Bodycams: essential for good law enforcement, or a privacy risk?
Did you ever come across bodycams in your place of residence and if so, how do you think the use of bodycams alter the relationship between the public and (transport) police?
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche posts encouraging half year results
This content was published on
Sales were up three per cent in Swiss francs to SFr24.6 billion. Roche said that major drivers included the group’s leading cancer medicines, with sales of its oncology portofolio rising by nine per cent to SFr11.1 billion. But it noted that the net-profit increase was primarily achieved as a result of much lower charges incurred…
This content was published on
This could lead to the drug Avastin being taken off of the American market, as US government health scientists announced on Friday. The Food and Drug Administration (FDA) approved Avastin in 2008, basing its decision on early-stage trials. However, follow-up studies done by Swiss pharmaceutical giant Roche indicate that the drug does not significantly extend…
This content was published on
Roche received two “shame” prizes at the Public Eye Awards in Davos for conducting research on transplant patients in China without knowing the origin of the organs donated. The Basel-based company won the 2010 Swiss Award in addition to the People’s Award – the latter based on an online poll. The presentation is held each…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.